Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative

Circulation. Cardiovascular Quality and Outcomes
Kamil F FaridiRobert W Yeh

Abstract

Background Ticagrelor and prasugrel are potent P2Y12 inhibitors with superior efficacy compared with clopidogrel among patients with ST-segment-elevation myocardial infarction (STEMI), though use in recent practice is not well described. In this retrospective study, we assessed trends, predictors, and variation in use of P2Y12 inhibitors in patients with STEMI in the United States. Methods and Results We identified 169 505 STEMI patients in the Chest Pain-Myocardial Infarction Registry from October 2013 through March 2017. We determined national utilization rates of P2Y12 inhibitors at discharge, patient predictors for each medication, and variation in use between hospitals. In a subset of 9655 Medicare patients ≥65 years old, we compared 1-year adjusted risks of death, myocardial infarction, stroke, and bleeding based on hospital quartile of potent P2Y12 inhibitor use. Rates of ticagrelor use increased from 18.0% to 44.0%, while rates of prasugrel and clopidogrel use decreased from 24.6% to 13.5% and 57.4% to 42.6%, respectively. Prior percutaneous coronary intervention was the strongest clinical predictor for use of ticagrelor (adjusted odds ratio, 1.13 [95% CI, 1.09-1.18]) and prasugrel (adjusted odds ratio, 1.27 [95% CI, 1....Continue Reading

References

Feb 23, 2007·International Journal of Clinical Practice·R ZambahariW H Chow
May 3, 2007·JAMA : the Journal of the American Medical Association·Keith A A FoxUNKNOWN GRACE Investigators
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Jun 19, 2010·The New England Journal of Medicine·Robert W YehAlan S Go
Jul 17, 2010·Journal of the American College of Cardiology·Matthew T RoeJohn S Rumsfeld
Dec 29, 2010·The American Journal of Medicine·David D McManusRobert J Goldberg
Sep 25, 2012·Journal of the American College of Cardiology·John C MessengerUNKNOWN NCDR Science and Quality Oversight Committee Data Quality Workgroup
May 20, 2015·Research in Social & Administrative Pharmacy : RSAP·Shellie L KeastDonald Harrison
Mar 30, 2016·JAMA : the Journal of the American Medical Association·Robert W YehUNKNOWN DAPT Study Investigators
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Nicolas DanchinUNKNOWN PIRAEUS group
Mar 18, 2017·Journal of the American College of Cardiology·Maria-Corina SerbanRobert S Rosenson
Nov 15, 2017·Therapeutic Advances in Cardiovascular Disease·Diego CastiniStefano Carugo
May 17, 2018·Cardiovascular Drugs and Therapy·Ioannis AndreouDimitrios Alexopoulos
Jun 11, 2018·Journal of the American Heart Association·Sukhdeep S BasraHani Jneid
Nov 28, 2018·Journal of Managed Care & Specialty Pharmacy·Daniel L ShawJoseph S Ross
Sep 3, 2019·The New England Journal of Medicine·Stefanie SchüpkeUNKNOWN ISAR-REACT 5 Trial Investigators

❮ Previous
Next ❯

Citations

Jun 12, 2021·European Heart Journal. Cardiovascular Pharmacotherapy·Francesco FranchiDominick J Angiolillo

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.